

CHAPTER 6

6. References

1. Ubersax JA, Ferrell JE Jr. Mechanisms of specificity in protein phosphorylation. *Nat Rev Mol Cell Biol.* 2007, 8(7), 530-41.
2. Cohen P. Protein kinases-the major drug targets of the twenty-first century. *Nat Rev Drug Discov.* 2002, 1(4), 309-15.
3. Holzer H, Duntze W. *Annual Review of Biochemistry*, 1971, 40, 345-374.
4. Heath CM, Stahl PD, Barbieri MA. Lipid kinases play crucial and multiple roles in membrane trafficking and signaling. *Histology and Histopathology.* 2003, 18(3), 989–998.
5. Khan WN, Alt FW, Gerstein RM, Malynn BA, Larsson I, Rathbun G, Davidson L, Muller S, Kantor AB, Herzenberg LA, et al. Defective B cell development and function in BTK-deficient mice. *Immunity.* 1995, 3, 283–99.
6. Bolen JB. Protein tyrosine kinases in the initiation of antigen receptor signaling. *Curr Opin Immunol.* 1995, 7(3), 306-11.
7. Mano H. Tec family of protein-tyrosine kinases: an overview of their structure and function. *Cytokine Growth Factor Rev.* 1999,10(3-4), 267-80.
8. August A, Sadra A, Dupont B, Hanafusa H. Src-induced activation of inducible T cell kinase (ITK) requires phosphatidylinositol 3-kinase activity and the Pleckstrin homology domain of inducible T cell kinase. *Proc Natl Acad Sci U S A.* 1997, 94(21), 11227-32.
9. Salim K, Bottomley MJ, Querfurth E, Zvelebil MJ, Gout I, Scaife R, et al. Distinct specificity in the recognition of phosphoinositide by the pleckstrin

- homology domains of dynamine and Bruton's tyrosine kinase. *EMBO J.* 1996, 15(22), 6241-50.
- 10.** Jiang Y, Ma W, Wan Y, Kozasa T, Hattori S, Huang XY. The G protein G alpha12 stimulates Bruton's tyrosine kinase and a rasGAP through a conserved PH/BM domain. *Nature.* 1998, 395(6704), 808-13.
- 11.** Tsukada S, Simon MI, Witte ON, Katz A. Binding of beta gamma subunits of heterotrimeric G proteins to the PH domain of Bruton tyrosine kinase. *Proc Natl Acad Sci U S A.* 1994, 91(23), 11256-60.
- 12.** Hyvonen M, Saraste M. Structure of the PH domain and BTK motif from Bruton's tyrosine kinase: molecular explanations for X-linked agammaglobulinaemia. *EMBO J.* 1997, 16(12), 3396-404.
- 13.** Rawlings DJ, Scharenberg AM, Park H, Wahl MI, Lin S, Kato RM, et al. Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases. *Science.* 1996, 271(5250), 822-5.
- 14.** Andreotti AH, Bunnell SC, Feng S, Berg LJ, Schreiber SL. Regulatory intramolecular association in a tyrosine kinase of the Tec family. *Nature.* 1997, 385(6611), 93-7.
- 15.** Yamashita Y, Miyazato A, Ohya K, Ikeda U, Shimada K, Miura Y, et al. Deletion of Src homology 3 domain results in constitutive activation of Tec protein-tyrosine kinase. *Jpn J Cancer Res.* 1996, 87(11), 1106-10.
- 16.** Backesjo CM, Vargas L, Superti-Furga G, Smith CI. Phosphorylation of Bruton's tyrosine kinase by c-Abl. *Biochem Biophys Res Commun.* 2002, 299(3), 510-5.

17. Guinamard R, Aspenstrom P, Fougereau M, Chavier P, Guillemot JC. Tyrosine phosphorylation of the Wiskott-Aldrich syndrome protein by Lyn and BTK is regulated by CDC42. *FEBS Lett.* 1998. 434(3), 431-6.
18. Guinamard R, Fougereau M, Seckinger P. The SH3 domain of Bruton's tyrosine kinase interacts with Vav, Sam68 and EWS. *Scand J Immunol.* 1997, 45(6):587-95.
19. Park H, Wahl MI, Afar DE, Turck CW, Rawlings DJ, Tam C, et al. Regulation of BTK function by a major autophosphorylation site within the SH3 domain. *Immunity.* 1996, 4(5), 515-25.
20. Ohya K, Kajigaya S, Kitanaka A, Yoshida K, Miyazato A, Yamashita Y, et al. Molecular cloning of a docking protein, BRDG1, that acts downstream of the Tec tyrosine kinase. *Proc Natl Acad Sci U S A.* 1999, 96(21), 11976-81.
21. Oppermann FS, Gnad F, Olsen JV, Hornberger R, Greff Z, Keri G, et al. Large-scale proteomics analysis of the human kinome. *Mol Cell Proteomics.* 2009, 8(7), 1751-64.
22. Murphy K. *Janeway's Immunobiology* (8th ed.). 2012, New York, Garland Science.
23. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. *B Cells and Antibodies. Molecular Biology of the Cell* (4th ed.), 2002.
24. Althwaiqeb SA, Bordoni B. *Histology, B Cell Lymphocyte.* 2022, StatPearls [Internet], Treasure Island (FL), StatPearls Publishing.
25. Chapman J, Zhang Y. *Histology, Hematopoiesis.* 2022, StatPearls [Internet], Treasure Island (FL), StatPearls Publishing.
26. Null M, Arbor TC, Agarwal M. *Anatomy, Lymphatic System.* 2023, StatPearls [Internet], Treasure Island (FL), StatPearls Publishing.

27. Ozdowski L, Gupta V. Physiology, Lymphatic System. 2022, StatPearls [Internet], Treasure Island (FL), StatPearls Publishing.
28. Aziz M, Iheanacho F, Hashmi MF. Physiology, Antibody. 2022, StatPearls [Internet], Treasure Island (FL), StatPearls Publishing.
29. Justiz Vaillant AA, Jamal Z, Patel P, Ramphul K. Immunoglobulin. 2022, StatPearls [Internet], Treasure Island (FL), StatPearls Publishing.
30. Tanaka S, Baba Y. B Cell Receptor Signaling. *Adv Exp Med Biol.* 2020,1254, 23-36.
31. Grubbs H, Kahwaji CI. Physiology, Active Immunity. 2022, StatPearls [Internet], Treasure Island (FL), StatPearls Publishing.
32. Sauls RS, McCausland C, Taylor BN. Histology, T-Cell Lymphocyte. 2022, StatPearls [Internet], Treasure Island (FL), StatPearls Publishing.
33. Allen HC, Sharma P. Histology, Plasma Cells. 2022, StatPearls [Internet], Treasure Island (FL), StatPearls Publishing.
34. David J. Rawlings et al., Mutation of Unique Region of Bruton's Tyrosine Kinase in Immunodeficient XID Mice. *Science*, 1993, 261,358-361.
35. Hashimoto A, Okada H, Jiang A, Kurosaki M, Greenberg S, Clark EA, Kurosaki T. Involvement of guanosine triphosphatase and phospholipase C-gamma2 in extracellular signal-regulated kinase, c-Jun NH2-terminal kinase, and p38 mitogen-activated protein kinase activation by the B cell antigen receptor. *J Exp Med.* 1998, 188, 1287–95.
36. Reth M. Antigen receptor tail clue. *Nature.* 1989, 338(6214), 383-4.
37. O'Rourke LM, Tooze R, Turner M, Sandoval DM, Carter RH, Tybulewicz VL, Fearon DT. CD19 as a membrane-anchored adaptor protein of B lymphocytes:

- costimulation of lipid and protein kinases by recruitment of Vav. *Immunity*. 1998, 8, 635–45.
- 38.** Okada T, Maeda A, Iwamatsu A, Gotoh K, Kurosaki T. BCAP: the tyrosine kinase substrate that connects B cell receptor to phosphoinositide 3-kinase activation. *Immunity*. 2000,13, 817–27.
- 39.** Saito K, Scharenberg AM, Kinet JP. Interaction between the BTK PH domain and phosphatidylinositol-3,4,5-trisphosphate directly regulates BTK. *J Biol Chem*. 2001,276, 16201–6.
- 40.** Engels N, König LM, Heemann C, Lutz J, Tsubata T, Griep S, Schrader V, Wienands J. Recruitment of the cytoplasmic adaptor Grb2 to surface IgG and IgE provides antigen receptor-intrinsic co stimulation to class-switched B cells. *Nat Immunol*. 2009, 10, 1018-25.
- 41.** Kim YJ, Sekiya F, Poulin B, Bae YS, Rhee SG. Mechanism of B-cell receptor-induced phosphorylation and activation of phospholipase C-gamma2. *Mol Cell Biol*. 2004, 24, 9986–99.
- 42.** Petro JB, Rahman SM, Ballard DW, Khan WN. Bruton's tyrosine kinase is required for activation of I kappaB kinase and nuclear factor kappaB in response to B cell receptor engagement. *J Exp Med*. 2000, 191, 1745–54.
- 43.** Bajpai UD, Zhang K, Teutsch M, Sen R, Wortis HH. Bruton's tyrosine kinase links the B cell receptor to nuclear factor kappaB activation. *J Exp Med*. 2000, 191, 1735–44.
- 44.** Manning BD, Toker A. AKT/PKB signaling: navigating the network. *Cell*. 2017, 169, 381–405.

45. Craxton A, Jiang A, Kurosaki T, Clark EA. Syk and Bruton's tyrosine kinase are required for B cell antigen receptor-mediated activation of the kinase Akt. *J Biol Chem.* 1999, 274, 30644–50.
46. Engels N, Konig LM, Schulze W, Radtke D, Vanshylla K, Lutz J, Winkler TH, Nitschke L, Wienands J. The immunoglobulin tail tyrosine motif upgrades memory-type BCRs by incorporating a Grb2-Btk signalling module. *Nat Commun.* 2014, 5, 5456.
47. Ritter SL, Hall RA. Fine-tuning of GPCR activity by receptor-interacting proteins. *Nat Rev Mol Cell Biol.* 2009, 10, 819–30.
48. Okada T, Ngo VN, Ekland EH, Forster R, Lipp M, Littman DR, Cyster JG. Chemokine requirements for B cell entry to lymph nodes and Peyer's patches. *J Exp Med.* 2002, 196, 65–75.
49. Servant G, Weiner OD, Herzmark P, Balla T, Sedat JW, Bourne HR. Polarization of chemoattractant receptor signalling during neutrophil chemotaxis. *Science.* 2000, 287, 1037–40.
50. Lowry WE, Huang XY, Protein G. Beta gamma subunits act on the catalytic domain to stimulate Bruton's agammaglobulinemia tyrosine kinase. *J Biol Chem.* 2002, 277, 1488–92.
51. Tsukada S, Simon MI, Witte ON, Katz A. Binding of beta gamma subunits of hetero trimeric G proteins to the PH domain of Bruton tyrosine kinase. *Proc Natl Acad Sci U S A.* 1994, 91, 11256–60.
52. Bence K, Ma W, Kozasa T, Huang XY. Direct stimulation of Bruton's tyrosine kinase by G(q)-protein alpha-subunit. *Nature.* 1997, 389, 296–9.
53. de Gorter DJ, Beuling EA, Kersseboom R, Middendorp S, van Gils JM, Hendriks RW, Pals ST, Spaargaren M. Bruton's tyrosine kinase and

- phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. *Immunity*. 2007, 26, 93–104.
54. Rawlings DJ, Schwartz MA, Jackson SW, Meyer-Bahlburg A. Integration of B cell responses through toll-like receptors and antigen receptors. *Nat Rev Immunol*. 2012, 12, 282–94.
 55. Jefferies CA, Doyle S, Brunner C, Dunne A, Brint E, Wietek C, Walch E, Wirth T, O'Neill LA. Bruton's tyrosine kinase is a toll/interleukin-1 receptor domain binding protein that participates in nuclear factor kappaβ activation by toll like receptor 4. *J Biol Chem*. 2003;278:26258–64.
 56. Liu X, Zhan Z, Li D, Xu L, Ma F, Zhang P, Yao H, Cao X. Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase BTK. *Nat Immunol*. 2011, 12, 416–24.
 57. Gray P, Dunne A, Brikos C, Jefferies CA, Doyle SL, O'Neill LA. MyD88 adapter like (mal) is phosphorylated by Bruton's tyrosine kinase during TLR2 and TLR4 signal transduction. *J Biol Chem*. 2006, 281, 10489–95.
 58. Nimmerjahn F, Ravetch JV. Fc gamma receptors as regulators of immune responses. *Nat Rev Immunol*. 2008, 8, 34–47.
 59. Bournazos S, Wang TT, Ravetch JV. The role and function of Fc gamma receptors on myeloid cells. *Microbiol Spectr*. 2016, 4.
 60. Kawakami Y, Yao L, Miura T, Tsukada S, Witte ON, Kawakami T. Tyrosine phosphorylation and activation of Bruton tyrosine kinase upon fc epsilon RI cross-linking. *Mol Cell Biol*. 1994, 14, 5108–13.
 61. Justiz Vaillant AA, Stang CM. Lymphoproliferative Disorders. 2022, StatPearls [Internet], Treasure Island (FL), StatPearls Publishing.

62. Justiz Vaillant AA, Ramphul K. Antibody Deficiency Disorder. 2022, StatPearls [Internet], Treasure Island (FL), StatPearls Publishing.
63. Kumar V, Abbas AK, Aster Robbins JC. Diseases of white blood cells, lymph nodes, spleen, and thymus. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Philadelphia, Elsevier. 2015, 579-628.
64. Davis S. Nutritional factors and the development of non-Hodgkin's lymphoma: A review of the evidence. *Cancer Research*. 1992, 52, 5492s-5495s.
65. Paltiel O, Schmit T, Adler B, et al. The incidence of lymphoma in first-degree relatives of patients with Hodgkin's disease and non-Hodgkin's lymphoma: Results and limitations of a registry-linked study. *Cancer*. 2000, 88, 2357-2366.
66. Scherr PA, Hutchison GB, Neiman RS. Non-Hodgkin's lymphoma and occupational exposure. *Cancer Research*. 1992, 52, 5503s-5509s.
67. Vineis P, Faggiano F, Tedeschi M, et al. Incidence rates of lymphomas and soft-tissue sarcomas and environmental measurements of phenoxy herbicides. *Journal of the National Cancer Institute*. 1991, 83, 362-363.
68. Zahm SH, Blair A. Pesticides and non-Hodgkin's lymphoma. *Cancer Research*. 1992, 52, 5485s-5488s.
69. Correa A, Jackson L, Mohan A, et al. Use of hair dyes, hematopoietic neoplasms, and lymphomas: A literature review. II. Lymphomas and multiple myeloma. *Cancer Investigation*. 2000, 18, 467-479.
70. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 5th ed. Lyon, IARC, 2017, 189-342.
71. Kridel R, Sehn LH, Gascoyne RD. Pathogenesis of follicular lymphoma. *The Journal of Clinical Investigation*. 2012, 122, 3424.

72. Roulland S, Kelly RS, Morgado E, et al. t(14; 18) translocation: A predictive blood biomarker for follicular lymphoma. *Journal of Clinical Oncology*. 2014, 32(13), 1347-1355.
73. Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. *The Journal of Clinical Investigation*. 2012, 122(10), 3416-3423.
74. Swerdlow SH, Kuzu I, Dogan A, et al. The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testing. *Virchows Archiv*. 2016, 468(3), 259-275.
75. Hamadeh F, MacNamara SP, Aguilera NS, Swerdlow SH, Cook JR. MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma. *Modern Pathology*. 2015, 28(4), 564-574.
76. Molyneux EM, Rochford R, Griffin B, et al. Burkitt's lymphoma. *Lancet*. 2012, 379, 1234.
77. Love C, Sun Z, Jima D, et al. The genetic landscape of mutations in Burkitt lymphoma. *Nature Genetics*. 2012, 44(12), 1321-1325.
78. Dave SS, Fu K, Wright GW, et al. Lymphoma/Leukemia Molecular Profiling Project. Molecular diagnosis of Burkitt's lymphoma. *The New England Journal of Medicine*. 2006, 354(23), 2431-2442.
79. Swerdlow SH. Diagnosis of 'double hit' diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: When and how, FISH versus IHC. *Hematology, American Society of Hematology*. 2014, 2014(1), 90-99.
80. Yelin E. Work disability in rheumatic diseases. *Curr Opin Rheumatol*. 2007, 19(2), 91-96.

81. McInnes, IB, Schett DG. Cytokines in the pathogenesis of rheumatoid arthritis. *Nat Rev Immunol.* 2007, 7(6), 429-442.
82. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. *N Engl J Med.* 2001, 344(12), 907-916.
83. Lundberg KS, Nijenhuis ER, Vossenaar K, Palmblad WJ, van Venrooij L, Klareskog AJ, Zendman HE. Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. *Arthritis Res Ther.* 2005, 7(3), R458-467.
84. www.news-medical.net/health/Rheumatoid-Arthritis-History.aspx.
85. Gomez-Puerta JA, Mócsai A. Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis. *Curr Top Med Chem.* 2013, 13(6), 760-73.
86. Arneson LC, Carroll KJ, Ruderman EM. Bruton's Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis. *Immunotargets Ther.* 2021, 10, 333-342.
87. Sabour J. B-Cell Lymphoma Treatment Options. Published online on March 07, 2022. <https://www.verywellhealth.com/b-cell-lymphoma-treatment>.
88. Hendriks, R. W.; Yuvaraj, S.; Kil, L. P. *Nat. Rev. Cancer* 2014, 14, 219–232.
89. Whang, J. A.; Chang, B. Y. *Drug Discov. Today* 2014, 19, 1200–1204.
90. de Weers M, Verschuren MC, Kraakman EM, Mensink RG, Schuurman RK, van Dongen JJ, Hendriks RW. *Eur. J. Immunol.* 1993, 23, 3109–3114.
91. Katz FE, Lovering RC, Bradley LA, Rigley KP, Brown D, Cotter F, Chessells JM, Levinsky RJ, Kinnon C. *Leukemia.* 1994, 8, 574–577.
92. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang J, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne

- RD, Connors JM, Johnson NA, Rimsza LM, Campo E, Jaffe ES, Wilson WH, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM. *Nature*. 2010, 463, 88–92.
- 93.** Hendriks RW, Bredius RG, Pike-Overzet K, Staal FJ. Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man. *Expert Opin. Ther. Targets*. 2011, 15, 1003–1021.
- 94.** Honigberg LA, Smith AM, Sirisawad M, Verner E, Louny D, Chang B, Li S, Pan Z, Thamm DH, Miller RA, Buggy JJ. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. *Proc. Natl. Acad. Sci. U. S. A.* 2010, 107(29), 13075–13080.
- 95.** Xu D, Kim Y, Postelnek J, Vu MD, Hu DQ, Liao C, Bradshaw M, Hsu J, Zhang J, Pashine A, Srinivasan D, Woods J, Levin A, O’Mahony A, Owens TD, Lou Y, Hill RJ, Narula S, deMartino J, Fine JS. RN486, a selective Bruton’s tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents. *J. Pharmacol. Exp. Ther.* 2012, 341(1), 90–103.
- 96.** Di Paolo JA, Huang T, Balazs M, Barbosa J, Barck KH, Bravo BJ, Carano RAD, Darrow J, Davies DR, DeForge LE, Diehl L, Ferrando R, Gallion SL, Giannetti AM, Gribbling P, Hurez V, Hymowitz SG, Jones R, Kropf JE, Lee WP, Maciejewski PM, Mitchell SA, Rong H, Staker BL, Whitney JA, Yeh S, Young WB, C. Yu, J. Zhang, K. Reif, K.S. Currie, Specific BTK inhibition suppresses B cell– and myeloid cell–mediated arthritis, *Nat. Chem. Biol.* 2011, 7(1), 41–50.

97. Rankin AL, Seth N, Keegan S, Andreyeva T, Cook TA, Edmonds J, Mathialagan N, Benson MJ, Syed J, Zhan Y, Benoit SE, Miyashiro JS, Wood N, Mohan S, Peeva E, Ramaiah SK, Messing D, Homer BL, Dunussi-Joannopoulos K, Nickerson-Nutter CL, Schnute ME, Douhan J. Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis. *J. Immunol.* 2013, 191(9) 4540–4550.
98. Gillooly KM, Pulicicchio C, Pattoli MA, Cheng L, Skala S, Heimrich EM, McIntyre KW, Taylor TL, Kukral DW, Dudhgaonkar S, Nagar J, Banas D, Watterson SH, Tino JA, Fura A, Burke JR, Reddy SV. Bruton's tyrosine kinase Inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care. *PLoSOne.* 2017, 12(7), e0181782.
99. Crawford JJ, Johnson AR, Misner DL, Belmont LD, Castanedo G, Choy R, Coraggio M, Dong L, Eigenbrot C, Erickson R, Ghilardi N, Hau J, Katewa A, Kohli PB, Lee W, Lubach JW, McKenzie BS, Ortwine DF, Schutt L, Tay S, Wei B, Reif K, Liu L, Wong H, Young WB. Discovery of GDC-0853: a potent, selective, and non-covalent Bruton's tyrosine kinase inhibitor in early clinical development. *J. Med. Chem.* 2018, 61, 2227-2245.
100. Haselmayer P, Camps M, Liu-Bujalski L, Nguyen N, Morandi F, Head J, O'Mahony A, Zimmerli SC, Bruns L, Bender AT, Schroeder P, Grenningloh R. Efficacy and pharmacodynamic modeling of the BTK Inhibitor Evobrutinib in autoimmune disease models. *J. Immunol.* 2019, 202. 2888–2906.
101. Molina-Cerrillo J, Alonso-Gordoa T, Gajate P, Grande E. Bruton's tyrosine kinase (BTK) as a promising target in solid tumors. *Cancer Treatment Reviews.* 2017, 58, 41.

102. De CS, Kurian J, Dufresne C, Mittermaier AK, Moitessier N. Covalent inhibitors design and discovery. *European Journal of Medicinal Chemistry*. 2017, 138, 96-114.
103. Pan Z, Scheerens H, Li SJ, Schultz BE, Sprengeler PA, Burrill LC, Mendonca RV, Sweeney MD, Scott KC, Grothaus PG, Jeffery DA, Spoerke JM, Honigberg LA, Young PR, Dalrymple SA, Palmer JT. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. *ChemMedChem*. 2007, 2(1), 58–61.
104. US Food and Drug Administration. Approved Drugs: Ibrutinib. Available at: [https://wayback.archiveit.org/7993/20170111231706, http://www.fda.gov/Drugs/Information/OnDrugs/ApprovedDrugs/ucm374857.htm](https://wayback.archiveit.org/7993/20170111231706/http://www.fda.gov/Drugs/Information/OnDrugs/ApprovedDrugs/ucm374857.htm).
105. De Vries R, Smit JW, Hellemans P, Jiao J, Murphy J, Skee D, Snoeys J, Sukbuntherng J, Vliegen M, De Zwart L, Mannaert E, De Jong J. Stable isotope-labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults. *Br. J. Clin. Pharmacol*. 2016, 81(2), 235–245.
106. Eisenmann ED, Fu Q, Muhowski EM, Jin Y, Uddin ME, Garrison DA, Weber RH, Woyach JA, Byrd JC, Sparreboom A, Baker SD. Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition. *Cancer Research Communications*. 2021, 1(2), 79–89.
107. Furman RR, Cheng S, Lu P, Setty M, Perez AR, Guo A, et al. Ibrutinib resistance in chronic lymphocytic leukemia. *N Engl J Med*. 2014, 370, 2352-2354.

108. Byrd JC, Harrington BH, O'Brien S, Jones JA, Schuh AS, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang XL, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman RR. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. *N. Engl. J. Med.* 2016, 374, 323-332.
109. Sawalha Y, Bond DA, Alinari L. Evaluating the therapeutic potential of Zanubrutinib in the treatment of relapsed/refractory mantle cell lymphoma: evidence to date. *OncoTargets and Therapy.* 2020, 13, 6573–6581.
110. Lynch Jr. TJ, Kim ES, Eaby B, Garey J, West DP, Lacouture ME. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. *Oncologist.* 2007, 12(5), 610-21.
111. Alsadhan A, Cheung J, Gulrajani M, Gaglione EM, Nierma P, Hamdy A, Izumi R, Bibikova E, Patel P, Sun C, Covey T, Herman SEM, Wiestner A. Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib. *Clin. Cancer Res.* 2020, 26 (12), 2800-2809.
112. Estupinan TY, Berglof A, Zain R, Smith CIE, Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects. *Front. Cell Dev. Biol.* 2002, 9, 630942.
113. Dhillon S. Tirabrutinib: first approval, *Drugs.* 2020, 80(8),835–840.
114. Watterson SH, Liu QJ, Bertrand MB, Batt DG, Li L, Pattoli MA, Skala S, Cheng LH, Obermeier MT, Moore R, Yang Z, Vickery R, Elzinga PA, Discenza L, D'Arienzo C, Gillooly KM, Taylor TL, Pulicicchio C, Zhang YF, Heimrich E, McIntyre KW, Ruan Q, Westhouse RA, Catlett IM, Zheng NY,

- Chaudhry C, Dai J, Galella MA, Tebben AJ, Pokross M, Li JQ, Zhao RL, Smith D, Rampulla R, Allentoff A, Wallace MA, Mathur A, Salter-Cid L, Macor JE, Carter PH, Fura A, Burke JM, Tino JA. Discovery of Branebrutinib (BMS-986195): a Strategy for Identifying a highly potent and selective covalent inhibitor providing rapid *in vivo* inactivation of Bruton's tyrosine kinase (BTK). *J. Med. Chem.* 2019, 62, 3228-3250.
- 115.** D. Isenberg, R. Furie, N.S. Jones, P. Guibord, J. Galanter, C. Lee, A. McGregor, B. Toth, J. Rae, O. Hwang, R. Desai, A. Lokku, N. Ramamoorthi, J.A. Hackney, P. Miranda, V.A. de Souza, J.J. Jaller-Raad, A. Maura Fernandes, R. Garcia Salinas, Chinn LW, Townsend MJ, Morimoto AM, Tuckwell K. Efficacy, safety, and pharmacodynamic effects of the Bruton's tyrosine kinase inhibitor Fenebrutinib (GDC-0853) in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled trial. *Arthritis Rheumatol.* 2021, 73(10), 1835–1846.
- 116.** Singh J, Petter RC, Baillie TA, Whitty A. The Resurgence of Covalent Drugs. *Nat. Rev. Drug Discov.* 2011, 10, 307–317.
- 117.** Kalgutkar AS, Dalvie DK. Drug discovery for a new generation of covalent drugs. *Expert Opin. Drug Discov.* 2015, 7, 561–581.
- 118.** Liu Q, Sabnis Y, Zhao Z, Zhang T, Buhrlage SJ, Jones LH, Gray NS. Developing irreversible inhibitors of the protein kinase cysteinome. *Chem. Biol.* 2013, 20, 146–159.
- 119.** Bender AT, Gardberg A, Pereira A, Johnson T, Wu Y, Grenningloh R, Head J, Morandi F, Haselmayer P, Liu-Bujalski L. Elucidation of BTK Inhibitor's Selectivity for Different Pathways. *Molecular Pharmacology.* 2017, 91(3), 208-219.

120. Zhu K, Borrelli KW, Greenwood JR, Day T, Abel R, Farid RS, Harder E. Docking covalent inhibitors: a parameter free approach to pose prediction and scoring, *J. Chem. Inf. Model.* 2014, 54(7). 1932–1940.
121. Schrödinger Release, 2019-1: LigPrep, Schrödinger, LLC, New York, NY, 2019.
122. Wang J, Guo J, Zhan J, Bu H, Lin J. An in-vitro cocktail assay for assessing compound-mediated inhibition of six major cytochrome P450 enzymes. 2014, 4(4), 270-278.
123. Danker T, Moller C. Early identification of hERG liability in drug discovery programs by automated patch clamp. 2014, 5, 203.
124. Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. *Adv Drug Deliv Rev.* 2001, 46(1-3), 27-43.
125. Li P, Wang B, Zhang X, Batt SM, Besra GS, Zhang T, et al. Identification of novel benzothiopyranone compounds against *Mycobacterium tuberculosis* through scaffold morphing from benzothiazinones. *Eur J Med Chem.* 2018; 160:157-170.
126. Scales HE, Ierna M, Smith KM, et al. Assessment of murine collagen-induced arthritis by longitudinal non-invasive duplexed molecular optical imaging. *Rheumatology.* 2016, 55, 564-572.
127. Promega Corporation, <https://www.promega.com/-/media/files/resources/protocols/kinase-enzyme-appnotes/btk-kinase-assay-protocol.pdf>.
128. Yahiaoui A, Meadows SA, Sorensen RA, Cui ZH, Keegan KS, Brockett R, Chen G, Quéva C, Li L, Tannheimer SL. PI3K δ inhibitor idelalisib in

combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3K δ and BTK inhibitors. PLoS One. 2017, 12(2), e0171221.

- 129.** Luo FR, Yang Z, Camuso A, Smykla R, McGlinchey K, Fager K, et al. Dasatinib (BMS-354825) Pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Clin Cancer Res. 2006, 12(23), 7180-7186.
- 130.** Gaudio E, Tarantelli C, Kwee I, Barassi C, Bernasconi E, Rinaldi A, Ponzoni M, Cascione L, Targa A, Stathis A, Goodstal S, Zucca E, Berton F. Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas. Annals of Oncology. 2016, 27, 1123–1128.
- 131.** Asquith DL, Miller AM, McInnes IB, Liew FY. Animal models of rheumatoid arthritis. Eur. J. Immunol. 2009, 39, 2040-2044.
- 132.** Buscher B, Laakso S, Mascher H, Pusecker K, Doig M, Dillen L, Wagner-Redeker W, Pfeifer T, Delrat P, Timmerman P. Bioanalysis for plasma protein binding studies in drug discovery and drug development: views and recommendations of the European Bioanalysis Forum. Bioanalysis. 2014, 6(5), 673-682. 130.
- 133.** Raj J, Mohineesh, Ray R, Dogra TD, Raina A. Acute oral toxicity and histopathological study of combination of endosulfan and cypermethrin in wistar rats. Toxicol Int. 2013, 20(1), 61-7.